Probiotics and anti-infective resistance: modern concepts and new therapeutic possibilities
DOI: 10.32364/2618-8430-2023-6-2-184-191
E.V. Kanner1, A.L. Zaplatnikov2, I.D. Kanner3, I.M. Farber4
1Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russian Federation
2Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation
3Lomonosov Moscow State University, Moscow, Russian Federation
4I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
In recent years, pediatricians and epidemiologists have noted the emergence of some unfavorable trends in the child population health, namely: an increase in the number of allergic pathologies, autoimmune diseases, obesity, chronic nonspecific bowel diseases. Among the risk factors, changes in the composition of the intestinal microbiota occupy one of the first places. This review discusses numerous mechanisms to explain how gut bacteria can be interconnected with immunity or the development of concomitant diseases. The article describes in detail various strategies used to manage the gut microbiota for the prevention and treatment of diseases. The role of probiotic strains and their influence on various parts of the immune response are also described. Besides, the article presents the study data concerning the influence of probiotic drugs on the provision of immunological resistance in the human body. Understanding the mechanisms of interaction between the host and the microbiota and their regulation will allow us to determine individual therapeutic possibilities for the treatment of many diseases. The benefits of two strains — Lactobacillus plantarum CECT 7315 and CECT 7316 — which have a comprehensive effect on the intestinal microbiota and having well-expressed immunomodulatory properties are discussed.
Keywords: microbiota, gastrointestinal tract, innate immunity, commensals, probiotics, lactobacilli, vitamins.
For citation: Kanner E.V., Zaplatnikov A.L., Kanner I.D., Farber I.M. Probiotics and anti-infective resistance: modern concepts and new therapeutic possibilities. Russian Journal of Woman and Child Health. 2023;6(2):184–191 (in Russ.). DOI: 10.32364/2618-8430-2023-6-2-184-191.
About the authors:
Ekaterina V. Kanner — Dr. Sc. (Med.), senior researcher of the Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology of the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; 3A, Novogireevskaya str., Moscow, 111123, Russian Federation; ORCID iD 0000-0003-3204-1846.
Andrey L. Zaplatnikov — Dr. Sc. (Med.), Professor, Vice-chancellor for Instructional Work, Head of the Prof. N.N. Gavryushov Department of Neonatology, professor of the Acad. G.N. Speranskiy Department of Pediatrics, Russian Medical Academy of Continuous Professional Education; 2/1, Barrikadnaya str., Moscow, 125993, Russian Federation; ORCID iD 0000-0003-1303-8318.
Il'ya D. Kanner — 5th-grade student, Lomonosov Moscow State University; 1, Leninskie Gory, Moscow, 119991, Russian Federation; ORCID iD 0000-0003-4632-0547.
Irina M. Farber —C. Sc. (Med.), Assistant of the Department of Children's Diseases, N.F. Filatov Children's City Clinical Hospital, I.M. Sechenov First Moscow State Medical University (Sechenov University); 8, Build. 2, Trubetskaya str., Moscow, 119991, Russian Federation; ORCID iD 0000-0001-6919-6732.
Contact information: Ekaterina V. Kanner, e-mail: ekanner@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 02.03.2023.
Revised 27.03.2023.
Accepted 19.04.2023.
2. Ahern P.P., Maloy K.J. Understanding immune-microbiota interactions in the intestine. Immunology. 2020;159(1):4–14. DOI: 10.1111/imm.13150.
3. Hertli S., Zimmermann P. Molecular interactions between the intestinal microbiota and the host. Mol Microbiol. 2022;117(6):1297–1307. DOI: 10.11 11/mmi.14905.
4. Agus A., Planchais J., Sokol H. Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018;23(6):716–724. DOI: 10.1016/j.chom.2018.05.003.
5. Asadi A., Shadab Mehr N., Mohamadi M.H. et al. Obesity and gut-microbiota-brain axis: A narrative review. J Clin Lab Anal. 2022;36(5):e24420. DOI: 10.1002/jcla.24420.
6. Samuelson D.R., Welsh D.A., Shellito J.E. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085. DOI: 10.3389/fmicb.2015.01085.
7. Calder P.C., Ortega E.F., Meydani S.N. et al. Nutrition, Immunosenescence, and Infectious Disease: An Overview of the Scientific Evidence on Micronutrients and on Modulation of the Gut Microbiota. Adv Nutr. 2022;13(5):S1–S26. DOI: 10.1093/advances/nmac052.
8. Cani P.D. Human gut microbiome: Hopes, threats and promises. Gut. 2018;67:1716–1725. DOI: 10.1136/gutjnl-2018-316723.
9. Rooks M.G., Garrett W.S. Gut microbiota, metabolites and host immunity. Nat Rev Immunol. 2016;16:341–352. DOI: 10.1038/nri.2016.42.
10. Espírito Santo C., Caseiro C., Martins M.J. et al. Gut Microbiota, in the Halfway between Nutrition and Lung Function. Nutrients. 2021;13(5):1716. DOI: 10.3390/nu13051716.
11. Mowat A.M., Agace W.W. Regional specialization within the intestinal immune system. Nat Rev Immunol. 2014;14:667–685. DOI: 10.1038/nri3738.
12. Bain C.C., Mowat A.M. Macrophages in intestinal homeostasis and inflammation. Immunol Rev. 2014;260:102–117. DOI: 10.1111/imr.12192.
13. Groschwitz K.R., Hogan S.P. Intestinal barrier function: Molecular regulation and disease pathogenesis. J Allergy Clin Immunol. 2009;124:3–20. DOI: 10.1016/j.jaci.2009.05.038. quiz 21-2.
14. Hooper L.V., MacPherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat Rev Immunol. 2010;10:159–169. DOI: 10.1038/nri2710.
15. Belkaid Y., Hand T.W. Role of the Microbiota in Immunity and Inflammation. Cell. 2014;157:121–141. DOI: 10.1016/j.cell.2014.03.011.
16. Tsolis R.M., Bäumler A.J. Gastrointestinal host-pathogen interaction in the age of microbiome research. Curr Opin Microbiol. 2020;53:78–89. DOI: 10.1016/j.mib.2020.03.002.
17. Zheng L., Kelly C.J., Battista K.D. et al. Microbial-Derived Butyrate Promotes Epithelial Barrier Function through IL-10 Receptor–Dependent Repression of Claudin-2. J Immunol. 2017;199:2976–2984. DOI: 10.4049/jimmunol.1700105.
18. Furusawa Y., Obata Y., Fukuda S. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–450. DOI: 10.1038/nature12721.
19. Smith P.M., Howitt M.R., Panikov N. et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. Science. 2013;341:569–573. DOI: 10.1126/science.1241165.
20. Pandiyan P., Bhaskaran N., Zou M. et al. Microbiome Dependent Regulation of Tregs and Th17 Cells in Mucosa. Front Immunol. 2019;10:426. DOI: 10.3389/fimmu.2019.00426.
21. Lee N., Kim W.-U. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017;49:e340. DOI: 10.1038/emm.2017.36.
22. König J., Wells J., Cani P. et al. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol. 2016;7:e196. DOI: 10.1038/ctg.2016.54.
23. Paone P., Cani P.D. Mucus barrier, mucins and gut microbiota: The expected slimy partners? Gut. 2020;69:2232–2243. DOI: 10.1136/gutjnl-2020-322260.
24. Sundararaman A., Ray M., Ravindra P.V., Halami P.M. Role of probiotics to combat viral infections with emphasis on COVID-19. Appl Microbiol Biotechnol. 2020;104(19):8089–8104. DOI: 10.1007/s00253-020-10832-4.
25. Gordon S. Elie Metchnikoff: father of natural immunity. Eur J Immunol. 2008;38:3257–3264. DOI: 10.1002/eji.200838855.
26. Yadav M.K., Kumari I., Singh B. et al. Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Appl Microbiol Biotechnol. 2022;106(2):505–521. DOI: 10.1007/s00253-021-11646-8.
27. Kanauchi O., Andoh A., AbuBakar S., Yamamoto N. Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. Curr Pharm Des. 2018;24:710–717. DOI: 10.2174/1381612824666180116163411.
28. Hao Q., Lu Z., Dong B.R. et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895. DOI: 10.1002/14651858.CD006895.pub2.
29. Grudzien M., Rapak A. Effects of natural compounds on NK cell activation. J Immunol Res. 2018;2018:4868417–4868411. DOI: 10.1155/2018/4868417.
30. Belkaid Y., Hand T. Role of the Microbiota in immunity and inflammation. Cell. 2014;157:121–141. DOI: 10.1016/j.cell.2014.03.011.
31. Martinez V., López Q., Gassull M.A. et al. Strains of Lactobacillus plantarum as probiotics. European Patent. 2007; 07121817.6.
32. Bosch M., Rodriguez M., Garcia F. et al. Probiotic properties of Lactobacillus plantarum CECT 7315 and CECT 7316 isolated from faeces of healthy children. Lett Appl Microbiol. 2012;54(3):240–246. DOI: 10.1111/j.1472-765X.2011.03199.x.
33. Mañé J., Pedrosa E., Lorén V. et al. A mixture of Lactobacillus plantarum CECT 7315 and CECT 7316 enhances systemic immunity in elderly subjects. A dose-response, double-blind, placebo-controlled, randomized pilot trial. Nutr Hosp. 2011;26(1):228–235. PMID: 21519752.
34. Bosch M., Méndez M., Pérez M. et al. Lactobacillus plantarum CECT7315 and CECT7316 stimulate immunoglobulin production after influenza vaccination in elderly. Nutr Hosp. 2012;27(2):504–509. DOI: 10.1590/S0212-16112012000200023.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать